Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study - Burtness, B; Harrington, K J; Greil, R; KEYNOTE-048 Investigators (Lancet, 2019)
(10212):